Hematologic Articles & Analysis
37 articles found
Cancer treatment has witnessed transformative advancements over the past few decades, notably with the emergence of CAR-T (Chimeric Antigen Receptor T-cell) therapy. This revolutionary therapy harnesses the body's immune system by genetically engineering T-cells to target and destroy cancer cells. Among the pioneering companies at the forefront of this innovation is Alfa Cytology, renowned for ...
Fluorescence In Situ Hybridization (FISH) and Immunohistochemistry (IHC) are two powerful techniques widely used in biological and medical research. While each has its strengths, the combination of these methods—ImmunoFISH—offers a unique and comprehensive approach to investigation at the cellular and tissue levels. Understanding the Techniques FISH is primarily utilized for detecting ...
In recent years, the fight against cancer has seen significant advances, particularly with the emergence of targeted therapy. Among the most promising strategies in this domain is the development of radioactive drug conjugates(RDCs). These innovative therapeutic agents combine the targeting capabilities of antibodies with the cytotoxic effects of radioactive isotopes, providing a powerful ...
Building innovative solutions to common laboratory challenges has been Advanced Instruments’ mission since 1955, a time when electronic automation was just beginning to be applied to laboratory methods. Throughout its 70-year history, Advanced Instruments’ osmometers have helped global clinical laboratories revolutionise workflow efficiency on the chemistry bench. Over the last two ...
ESMO updated its recommendations for NGS in advanced cancers this year, urging broader use of NGS in additional cancer types and the inclusion of tumor-agnostic biomarkers. The ESMO Precision Medicine Working Group (PMWG) first published its recommendations for when to use next-generation sequencing (NGS) in routine practice for patients with metastatic cancers in 20201. At that time, based ...
Anti-G reactivity in red cell antibody detection and identification studies mimics the presence of both anti-D and anti-C. This can complicate decision making in pregnant patients. It is important to determine if anti-D is present for guiding Rh immune globulin prophylaxis. ...
Coupling drugs combine the precise targeting and potent killing properties, has become a widely recognized form of medication in recent years. Radioactive drug conjugates (RDCs), as a particular form of coupling drugs, are formed by combining radioactive isotopes with disease-targeting molecules. According to the application of RDCs, they can be divided into two main categories: diagnostic RDCs ...
Relationship Between Immunity, Inflammation and Cancer Immunity is an act of self-protection of the body. The immune response is divided into specific and non-specific. The antigen and antibody responses are generally referred to as specific immune responses, which require the participation of B cells and T cells. Other immune cells such as macrophages and NK cells mediate non-specific immune ...
The Myc gene is one of the most important drivers of cancer in mice and humans. Myc also plays a newly discovered key role in aging, according to a new study in Cell Reports by researchers at UPMC Children's Hospital of Pittsburgh and the University of Pittsburgh School of Medicine. The study, led by Edward V. Prochownik, MD, UPMC Children's Hematology/Oncology Division and Paul C. Gaffney ...
Antibody-drug conjugates (ADCs), as emerging anticancer drugs, can deliver highly cytotoxic molecules directly to cancer cells to kill them. ADC is a monoclonal antibody covalently bound to cytotoxic chemical substances (payload) through linker. ADC linker plays a key role in the therapeutic effect of ADC, and its characteristics greatly affect the therapeutic index, pharmacodynamics and ...
Thymic Stromal Lymphopoietin (TSLP) is a multifunctional cytokine that acts on various cell types, including dendritic cells, T cells, B cells, neutrophils, mast cells, eosinophils, and innate lymphoid cells, affecting their maturation, survival, and recruitment. It is well-known for its role in promoting type 2 immune responses, such as allergic diseases. In 2021, a monoclonal antibody targeting ...
Unlike the development of most small or large molecules, which typically measures only one part or the metabolite for pharmacokinetic analysis, multiple parts of ADCs need to be measured to characterize their PK properties. Therefore, a thorough understanding of the clinical pharmacology of ADCs is critical for selecting a safe and effective dose for patients. Biological Analysis of ADC In order ...
Antibody-drug conjugates (ADCs) usually consist of monoclonal antibodies (mAbs) covalently linked to cytotoxic drugs via chemical linkers. With high specific targeting ability and strong killing effect, it has achieved precise and efficient removal of cancer cells, and has become one of the hot spots in the development of anticancer drugs. In 2000, the FDA first approved the ADC drug Mylotarg ...
Department of Immunology and Pathology, Monash University, Level 6, Burnet Tower, 89 Commercial Road, Melbourne, VIC 3004, Australia. Department of Clinical Haematology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre, 305 Grattan St., Parkville, VIC 3000, Australia. Immunology Division, Walter and Eliza Hall Institute, 1G Royal Parade, Parkville, VIC 3050, Australia. Sir Peter ...
The advent of immunotherapies for cancer, and more recently of cellular immunotherapies, has substantially altered the treatment landscape. In hematological malignancies, complete response rates to CAR-T cells can exceed 80%. These responses are often durable in nature and have attracted considerable excitement and investment in the development of cell therapies for an expanded range of ...
The day a person receives a cancer diagnosis is likely one of the worst days of their lives. For some new patients, the typical approach may be to seek care from a specialist at an NCCN-designated cancer center. But for the majority of Americans, it will be a community oncologist who guides them through their cancer journey. That’s why Adaptive recently partnered as a sponsor with ...
Celdara Medical, LLC today announced that the National Cancer Institute of the National Institutes of Health (NIH) has awarded a Small Business Innovation Research (SBIR) Phase I award to fund the company’s proof of concept studies on a new platform to improve chimeric antigen receptor (CAR) T cells efficacy to treat solid tumors. Dr. Joana Murad-Mabaera, who leads this effort, stated, ...
Researchers at Massachusetts General Hospital (MGH) have found that interferon gamma receptor (IFNgR) signaling is essential for the susceptibility of CAR-T cell immunotherapy to kill malignant gliomas. The same phenomenon has been observed in other solid tumors. The findings may partially explain why liquid and solid tumors respond very differently to CAR-T cell therapy. Chimeric antigen ...
Introduction Oral anticoagulant therapy (OAT) using warfarin (Coumadin) has surged in recent years due to an increased number of indications and its demonstrated effectiveness. The primary means of monitoring the response to warfarin is the Prothrombin Time (PT) test, which is measured in seconds. The increased use of OAT has led to the development of point-of-care (POC) portable monitoring ...
At present, chimeric antigen receptor T cell therapy (CAR-T) has made significant achievements in the treatment of specific hematological cancers, allowing patients with relapsed/refractory disease to survive longer and become healthier, but in clinical studies, cell therapy has actually not been successful in the treatment of patients with solid tumors, in part due to the lack of tumor targets ...